| pubmed-article:1883852 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0027061 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0036226 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0521324 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0030685 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0596235 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0680255 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0391871 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C1283071 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C1963578 | lld:lifeskim |
| pubmed-article:1883852 | lifeskim:mentions | umls-concept:C0052825 | lld:lifeskim |
| pubmed-article:1883852 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1883852 | pubmed:dateCreated | 1991-10-9 | lld:pubmed |
| pubmed-article:1883852 | pubmed:abstractText | The mechanism of doxorubicin-induced Ca2+ release from skeletal and cardiac muscle sarcoplasmic reticulum (SR) was studied by examining the effects of azumolene (a water soluble dantrolene analog) on doxorubicin-mediated Ca2+ release and ryanodine binding. Doxorubicin induced a rapid Ca2+ release from both skeletal and cardiac SR in a similar concentration range (EC50 = 5-10 microM). Maximal doxorubicin-induced Ca2+ release was seen at 2 and 0.2 microM Ca2+ for skeletal and cardiac SR, respectively. Addition of 400 microM azumolene caused approx. 30% inhibition of doxorubicin-induced Ca2+ release from both skeletal and cardiac SR; skeletal SR had significantly higher sensitivity to azumolene than cardiac SR. In the presence of Ca2+, doxorubicin increased [3H]ryanodine binding to both skeletal and cardiac SR; whereas in the absence of Ca2+, doxorubicin led to significant ryanodine binding to skeletal SR, but not to cardiac SR. In both types of SR, doxorubicin-activated, but not Ca2+ activated ryanodine binding was inhibited by azumolene. Azumolene sensitivity for inhibition of doxorubicin-activated ryanodine binding was much higher in skeletal SR than cardiac SR, consistent with the results for effects of azumolene on Ca2+ release. Our results are consistent with the possibility that azumolene inhibits doxorubicin binding by direct competition for the drug receptor(s). | lld:pubmed |
| pubmed-article:1883852 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1883852 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1883852 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1883852 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1883852 | pubmed:issn | 0006-3002 | lld:pubmed |
| pubmed-article:1883852 | pubmed:author | pubmed-author:KatzA MAM | lld:pubmed |
| pubmed-article:1883852 | pubmed:author | pubmed-author:KimD HDH | lld:pubmed |
| pubmed-article:1883852 | pubmed:author | pubmed-author:TianQQ | lld:pubmed |
| pubmed-article:1883852 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1883852 | pubmed:day | 13 | lld:pubmed |
| pubmed-article:1883852 | pubmed:volume | 1094 | lld:pubmed |
| pubmed-article:1883852 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1883852 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1883852 | pubmed:pagination | 27-34 | lld:pubmed |
| pubmed-article:1883852 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:meshHeading | pubmed-meshheading:1883852-... | lld:pubmed |
| pubmed-article:1883852 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1883852 | pubmed:articleTitle | Effects of azumolene on doxorubicin-induced Ca2+ release from skeletal and cardiac muscle sarcoplasmic reticulum. | lld:pubmed |
| pubmed-article:1883852 | pubmed:affiliation | Department of Medicine, University of Connecticut Health Center, Farmington 06030. | lld:pubmed |
| pubmed-article:1883852 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1883852 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1883852 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1883852 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1883852 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1883852 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1883852 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1883852 | lld:pubmed |
